PharmiWeb.com - Global Pharma News & Resources
28-Jun-2019

Systemic Lupus Erythematosus Market Size Poised to Touch USD 2.7 Bn by 2026

The Global Systemic Lupus Erythematosus Market Size is expected to reach USD 2.7 Billion by 2026 and growing CAGR around 7% during the forecast period 2018 - 2026.

Introduction of new natural or biological treatments, which will add to treatment options and drug costs, in the advancement pipeline is evaluated to fuel income age of the market. Certain new encouraging medications that are as of now in Phase III preliminaries are foreseen to enlarge the market as these medications may focus on the lupus nephritis tolerant subset with couple of compelling options and noteworthy neglected should be met. This factor is probably going to strongly affect the market as almost 50.0% of SLE patients endure with lupus nephritis.

Utilization of approved biologic, Benlysta, through clinical investigations, has uncovered exceptional upgrades and considerable decline in utilization of mitigating glucocorticoids in moderate SLE cases. GSK's present activities fixate on further expanding open doors for Benlysta. The organization is leading sign extension clinical preliminaries, mix treatment examines with rituximab, and new item improvement, to enlarge open doors for its treatment. Toward this path, ongoing dispatch of Benlysta's subcutaneous plan in a few nations is relied upon to help the SLE showcase over the conjecture time frame.

Free Download Sample Report Pages For Better Understanding at https://www.acumenresearchandconsulting.com/request-sample/1166

The global systemic lupus erythematosus market is segmented into drug classes, route of administration and region. On the basis of drug classes, the global Systemic lupus erythematosus market is segmented into NSAIDs, Corticosteroids, Antimalarials, Immunosuppressants, and Biologics. On the basis of route of administration, the global systemic lupus erythematosus market is segmented into Oral, Intravenous, and Subcutaneous. On the basis of region the global Systemic lupus erythematosus market is bifurcated into Europe, Latin America, North America, Middle East amp; Africa, and Asia Pacific.

North America ruled the market in 2018, with the U.S. at the front line. The district is anticipated to hold its situation through 2026, advancing at a CAGR of 8.2% amid the conjecture time frame. Higher pervasiveness of SLE combined with inclusion for strength medications and healthcare infrastructure framework is adding to the development of the local market. Europe was the second-biggest territorial market in 2017, which remained at a valuation of USD 397.6 million. This can be ascribed to the way that the five noteworthy European Union nations (Germany, U.K., Italy, Spain, and France) were the first to support Benlysta as an extra treatment for the treatment of dynamic SLE. Also, because of better inclusion approaches, there is a higher adoption of belimumab since it is accessible in the two details or formulations.

APAC, LATAM, and MEA trail behind, with low noticeable quality in the market. Low income age in these districts can be credited to numerous variables, including low rheumatologist to populace proportion, which averts treatment and conclusion at a beginning time. Also, regardless of accessibility of belimumab in these districts, the treatment isn't open to patients because of its cost and horrible repayment situation. In low-pay economies, larger part of the patients look for open consideration framework, which commonly does not give great therapeutic offices.

To Purchase this Premium Report at https://www.acumenresearchandconsulting.com/buy-now/0/1166

Biologics for autoimmune conditions enhance treatment to a huge extent and are progressively gaining physiciansrsquo; confidence. Benlysta, the principal biologic in the previous five decades, was endorsed by the FDA and EMA in 2011. Nonetheless, in nations, for example, the U.K., it was first rejected on grounds of horrible money saving advantage examination and later propelled in the year 2016, however with value concessions.

The key players catering to the global Systemic lupus erythematosus market are Roche, GlaxoSmithKline, Sanofi, Bayer, Pfizer, Novartis, Astra Zeneca, Aurinia Pharmaceuticals, and ImmuPharma. Significant strategic initiatives undertaken by global businesses include partnerships, new product launch, acquisitions. Among key systems, GlaxoSmithKline in a partnership with Roche is directing clinical trials with Benlysta and rituximab to decide their consolidated viability in treating extreme manifestations of SLE. Moreover, Novartis built up a biosimilar rituximab requiring little to no effort, which is utilized as an off name medication to fuel selection of organic treatments in creating areas. Market companies are concentrating on implementing new strategies for instance regional expansion, partnerships, mergers and acquisitions, new product launches, and distribution agreements to surge their revenue share. And also, growing Ramp;D investments paired with technical advancements to commercialize highly efficient products are expected to offer huge growth opportunities for industry participants.

TABLE OF CONTENT

CHAPTER 1. INDUSTRY OVERVIEW

1.1. Definition and Scope
1.1.1. Definition of Systemic Lupus Erythematosus
1.1.2. Market Segmentation
1.1.3. List of Abbreviations
1.2. Summary
1.2.1. Market Snapshot
1.2.2. Systemic Lupus Erythematosus Market By Drug Classes
1.2.2.1. Global Systemic Lupus Erythematosus Market Revenue and Growth Rate Comparison By Drug Classes (2015-2026)
1.2.2.2. Global Systemic Lupus Erythematosus Market Revenue Share By Drug Classes in 2017
1.2.2.3. NSAIDs
1.2.2.4. Corticosteroids
1.2.2.5. Antimalarials
1.2.2.6. Immunosuppressants
1.2.2.7. Biologics
1.2.2.8. Others
1.2.3. Systemic Lupus Erythematosus Market By Route of Administration
1.2.3.1. Global Systemic Lupus Erythematosus Market Revenue and Growth Rate Comparison By Route of Administration (2015-2026)
1.2.3.2. Global Systemic Lupus Erythematosus Market Revenue Share By Route of Administration in 2017
1.2.3.3. Oral
1.2.3.4. Intravenous
1.2.3.5. Subcutaneous
1.2.3.6. Others
1.2.4. Systemic Lupus Erythematosus Market by Geography
1.2.4.1. Global Systemic Lupus Erythematosus Market Revenue and Growth Rate Comparison by Geography (2015-2026)
1.2.4.2. North America Systemic Lupus Erythematosus Market Revenue and Growth Rate (2015-2026)
1.2.4.3. Europe Systemic Lupus Erythematosus Market Revenue and Growth Rate (2015-2026)
1.2.4.4. Asia-Pacific Systemic Lupus Erythematosus Market Revenue and Growth Rate (2015-2026)
1.2.4.5. Latin America Systemic Lupus Erythematosus Market Revenue and Growth Rate (2015-2026)
1.2.4.6. Middle East and Africa (MEA) Systemic Lupus Erythematosus Market Revenue and Growth Rate (2015-2026)

CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS

2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porterrsquo;s Five Forces Analysis
2.4.1. Bargaining Power of Suppliers
2.4.2. Bargaining Power of Buyers
2.4.3. Threat of Substitute
2.4.4. Threat of New Entrants
2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
2.6.1. Raw Material and Suppliers
2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2017
2.8.1. Player Positioning Analysis
2.8.2. Key Strategies Adopted By Leading Players

CHAPTER 3. MANUFACTURING PLANTS ANALYSIS

3.1. Capacity and Commercial Production Date of Global Systemic Lupus Erythematosus Major Manufacturers in 2017
3.2. Manufacturing Plants Distribution of Global Systemic Lupus Erythematosus Major Manufacturers in 2017
3.3. Ramp;D Status and Technology Source of Global Systemic Lupus Erythematosus Major Manufacturers in 2017
3.4. Raw Materials Sources Analysis of Global Systemic Lupus Erythematosus Major Manufacturers in 2017

CHAPTER 4. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET BY DRUG CLASSES

4.1. Global Systemic Lupus Erythematosus Revenue By Drug Classes
4.2. NSAIDs
4.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.3. Corticosteroids
4.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.4. Antimalarials
4.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.5. Immunosuppressants
4.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.6. Biologics
4.6.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.6.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.7. Others
4.7.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.7.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 5. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET BY ROUTE OF ADMINISTRATION

5.1. Global Systemic Lupus Erythematosus Revenue By Route of Administration
5.2. Oral
5.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.3. Intravenous
5.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.4. Subcutaneous
5.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.5. Others
5.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 6. NORTH AMERICA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET BY COUNTRY

6.1. North America Systemic Lupus Erythematosus Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.2. North America Systemic Lupus Erythematosus Market Revenue Share Comparison, 2015 amp; 2026 (%)
6.3. U.S.
6.3.1. U.S. Systemic Lupus Erythematosus Market Revenue and Forecast By Drug Classes, 2015 - 2026 ($Million)
6.3.2. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
6.4. Canada
6.4.1. Market Revenue and Forecast By Drug Classes, 2015 - 2026 ($Million)
6.4.2. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
6.5. Mexico
6.5.1. Market Revenue and Forecast By Drug Classes, 2015 - 2026 ($Million)
6.5.2. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)

CHAPTER 7. EUROPE SYSTEMIC LUPUS ERYTHEMATOSUS MARKET BY COUNTRY

7.1. Europe Systemic Lupus Erythematosus Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.2. Europe Systemic Lupus Erythematosus Market Revenue Share Comparison, 2015 amp; 2026 (%)
7.3. UK
7.3.1. Market Revenue and Forecast By Drug Classes, 2015 - 2026 ($Million)
7.3.2. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
7.4. Germany
7.4.1. Market Revenue and Forecast By Drug Classes, 2015 - 2026 ($Million)
7.4.2. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
7.5. France
7.5.1. Market Revenue and Forecast By Drug Classes, 2015 - 2026 ($Million)
7.5.2. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
7.6. Spain
7.6.1. Market Revenue and Forecast By Drug Classes, 2015 - 2026 ($Million)
7.6.2. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
7.7. Rest of Europe
7.7.1. Market Revenue and Forecast By Drug Classes, 2015 - 2026 ($Million)
7.7.2. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)

CHAPTER 8. ASIA-PACIFIC SYSTEMIC LUPUS ERYTHEMATOSUS MARKET BY COUNTRY

8.1. Asia-Pacific Systemic Lupus Erythematosus Market Revenue and Growth Rate, 2015 - 2026 ($Million)
8.2. Asia-Pacific Systemic Lupus Erythematosus Market Revenue Share Comparison, 2015 amp; 2026 (%)
8.3. China
8.3.1. Market Revenue and Forecast By Drug Classes, 2015 - 2026 ($Million)
8.3.2. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
8.4. Japan
8.4.1. Market Revenue and Forecast By Drug Classes, 2015 - 2026 ($Million)
8.4.2. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
8.5. India
8.5.1. Market Revenue and Forecast By Drug Classes, 2015 - 2026 ($Million)
8.5.2. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
8.6. Australia
8.6.1. Market Revenue and Forecast By Drug Classes, 2015 - 2026 ($Million)
8.6.2. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
8.7. South Korea
8.7.1. Market Revenue and Forecast By Drug Classes, 2015 - 2026 ($Million)
8.7.2. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
8.8. Rest of Asia-Pacific
8.8.1. Market Revenue and Forecast By Drug Classes, 2015 - 2026 ($Million)
8.8.2. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)

CHAPTER 9. LATIN AMERICA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET BY COUNTRY

9.1. Latin America Systemic Lupus Erythematosus Market Revenue and Growth Rate, 2015 - 2026 ($Million)
9.2. Latin America Systemic Lupus Erythematosus Market Revenue Share Comparison, 2015 amp; 2026 (%)
9.3. Brazil
9.3.1. Market Revenue and Forecast By Drug Classes, 2015 - 2026 ($Million)
9.3.2. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
9.4. Argentina
9.4.1. Market Revenue and Forecast By Drug Classes, 2015 - 2026 ($Million)
9.4.2. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
9.5. Rest of Latin America
9.5.1. Market Revenue and Forecast By Drug Classes, 2015 - 2026 ($Million)
9.5.2. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)

CHAPTER 10. MIDDLE EAST SYSTEMIC LUPUS ERYTHEMATOSUS MARKET BY COUNTRY

10.1. Middle East Systemic Lupus Erythematosus Market Revenue and Growth Rate, 2015 - 2026 ($Million)
10.2. Middle East Systemic Lupus Erythematosus Market Revenue Share Comparison, 2015 amp; 2026 (%)
10.3. Saudi Arabia
10.3.1. Market Revenue and Forecast By Drug Classes, 2015 - 2026 ($Million)
10.3.2. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
10.4. UAE
10.4.1. Market Revenue and Forecast By Drug Classes, 2015 - 2026 ($Million)
10.4.2. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
10.5. Rest of Middle East
10.5.1. Market Revenue and Forecast By Drug Classes, 2015 - 2026 ($Million)
10.5.2. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)

CHAPTER 11. AFRICA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET BY COUNTRY

11.1. Africa Systemic Lupus Erythematosus Market Revenue and Growth Rate, 2015 - 2026 ($Million)
11.2. Africa Systemic Lupus Erythematosus Market Revenue Share Comparison, 2015 amp; 2026 (%)
11.3. South Africa
11.3.1. Market Revenue and Forecast By Drug Classes, 2015 - 2026 ($Million)
11.3.2. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
11.4. Egypt
11.4.1. Market Revenue and Forecast By Drug Classes, 2015 - 2026 ($Million)
11.4.2. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
11.5. Rest of Africa
11.5.1. Market Revenue and Forecast By Drug Classes, 2015 - 2026 ($Million)
11.5.2. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)

CHAPTER 12. COMPANY PROFILE

12.1. Roche
12.1.1. Company Snapshot
12.1.2. Overview
12.1.3. Financial Overview
12.1.4. Product Portfolio
12.1.5. Key Developments
12.1.6. Strategies
12.2. GlaxoSmithKline
12.2.1. Company Snapshot
12.2.2. Overview
12.2.3. Financial Overview
12.2.4. Product Portfolio
12.2.5. Key Developments
12.2.6. Strategies
12.3. Sanofi
12.3.1. Company Snapshot
12.3.2. Overview
12.3.3. Financial Overview
12.3.4. Product Portfolio
12.3.5. Key Developments
12.3.6. Strategies
12.4. Bayer
12.4.1. Company Snapshot
12.4.2. Overview
12.4.3. Financial Overview
12.4.4. Product Portfolio
12.4.5. Key Developments
12.4.6. Strategies
12.5. Pfizer
12.5.1. Company Snapshot
12.5.2. Overview
12.5.3. Financial Overview
12.5.4. Product Portfolio
12.5.5. Key Developments
12.5.6. Strategies
12.6. Novartis
12.6.1. Company Snapshot
12.6.2. Overview
12.6.3. Financial Overview
12.6.4. Product Portfolio
12.6.5. Key Developments
12.6.6. Strategies
12.7. Astra Zeneca
12.7.1. Company Snapshot
12.7.2. Overview
12.7.3. Financial Overview
12.7.4. Product Portfolio
12.7.5. Key Developments
12.7.6. Strategies
12.8. Aurinia Pharmaceuticals
12.8.1. Company Snapshot
12.8.2. Overview
12.8.3. Financial Overview
12.8.4. Product Portfolio
12.8.5. Key Developments
12.8.6. Strategies
12.9. ImmuPharma
12.9.1. Company Snapshot
12.9.2. Overview
12.9.3. Financial Overview
12.9.4. Product Portfolio
12.9.5. Key Developments
12.9.6. Strategies
12.10. Others
12.10.1. Company Snapshot
12.10.2. Overview
12.10.3. Financial Overview
12.10.4. Product Portfolio
12.10.5. Key Developments
12.10.6. Strategies

CHAPTER 13. RESEARCH APPROACH

13.1. Research Methodology
13.1.1. Initial Data Search
13.1.2. Secondary Research
13.1.3. Primary Research
13.2. Assumptions and Scope

The report is readily available and can be dispatched immediately after payment confirmation.

Buy this Premium Research Report at https://www.acumenresearchandconsulting.com/buy-now/0/1166

Would like to place an order or any question, please feel free to contact atsales@acumenresearchandconsulting.com| +1 407 915 4157

About Acumen Research and Consulting:

Acumen Research and Consulting (ARC) is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to makefact baseddecisions on technology purchases and develop firm growth strategies to sustain market competition. With the team size of 100+ Analysts and collective industry experience of more than 200 years, Acumen Research and Consulting assures to deliver a combination of industry knowledge along with global and country level expertise.

Editor Details

Last Updated: 28-Jun-2019